Treatment with the programmed cell death-protein 1 (PD-1) immune checkpoint-targeting monoclonal antibodies (mAbs) pembrolizumab or nivolumab has significantly improved the overall survival of patients with various types of cancer. This evidence concerns the gene PDCD1 and cancer.